HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%)

Trial Details

NCT ID
NCT07169552
Phase
PHASE2
Sponsor
HC Biopharma Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HC010
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • 1\. Voluntarily participate in the study, communicate well with investigators, understand and voluntarily complete the study process according to t…
  • 2\. Male or female, aged ≥ 18 years at the time of signing the informed consent form.
  • 3\. Histologically or cytologically confirmed locally advanced or metastatic (stage IIIb\~IV) NSCLC (United States Cancer Confederation \[AJCC\] 8t…
  • 4\. Not previously receiving systemic therapy for locally advanced or metastatic NSCLC; not allowed if the last dose of prior treatment is \<6 mont…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →